Nurix Therapeutics, Inc.
Clinical trials sponsored by Nurix Therapeutics, Inc., explained in plain language.
A clinical-stage biopharmaceutical company developing treatments for cancer and other diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug takes aim at Hard-to-Treat blood cancers Results expected Jan 2027 (estimated)
-
New hope for Tough-to-Treat blood cancers: NX-5948 trial opens
Disease control Recruiting nowThis study tests an experimental drug called NX-5948 in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to prior treatments, including BTK and BCL-2 inhibitors. The main goal is to see if the drug can shrink o…
Phase 2 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for hard-to-treat blood cancers: phase 3 trial pits NX-5948 against standard therapy
Disease control Recruiting nowThis study compares two drugs, NX-5948 and pirtobrutinib, in about 620 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has returned or stopped responding after prior treatment with a BTK inhibitor. The main goal is to see which drug…
Phase 3 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug cocktail aims to tackle tough blood cancers
Disease control Recruiting nowThis study tests a new drug called NX-5948 (bexobrutideg) combined with other medicines (venetoclax, and possibly rituximab or obinutuzumab) in adults with B-cell lymphoma, chronic lymphocytic leukemia, or small lymphocytic lymphoma. The goal is to see if the combination is safe …
Phase 1/2 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New drug takes aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase study tests a new drug called NX-5948 in adults with advanced B-cell blood cancers (like certain leukemias and lymphomas) that have not responded to other treatments. The drug works by breaking down a protein (BTK) that helps these cancer cells grow. The main goa…
Phase 1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug takes aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial tests a new oral drug called NX-2127 in adults with advanced B-cell cancers (like certain leukemias and lymphomas) that have not responded to standard treatments. The drug works by breaking down a protein that helps cancer cells grow. The main goals are to …
Phase 1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New cancer drug NX-1607 enters first human trials
Disease control Recruiting nowThis early-stage trial tests a new drug called NX-1607 in adults with advanced cancers that have not responded to standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors. It includes people with several cancer types, such as ovarian, lung, an…
Phase 1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:25 UTC